Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eisai

European regulators OK Alzheimer's treatment Leqembi after initial doubts

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer

The Independent UK

European committee takes a second look at Alzheimer's drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

The Independent UK

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

What you need to know about lecanemab – the Alzheimer’s drug rejected for NHS use

The drug has been developed by Eisai, a Japanese pharmaceutical company, and is sold under the brand name Leqembi

The Independent UK

What is Lecanemab and who makes it? Alzheimer’s drug gets approval but will not be available on the NHS

NICE says drug is not cost effective and shares fears of side effects

Evening Standard

First drug to slow Alzheimer’s progression will not be made available on the NHS

The spending watchdog has recommended that a drug shown to slow the progression of Alzheimer’s disease should not be rolled out on the NHS.

The Independent UK

Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug

Biogen stock tumbled Friday after European regulators rejected its Eisai-partnered Alzheimer's treatment, citing steep side effects.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

FDA approves a second Alzheimer's drug that can modestly slow disease

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease

The Independent UK

Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower

Eli Lilly stock seesawed Tuesday after a Food and Drug Administration panel endorsed its Alzheimer's treatment, donanemab.

Investors Business Daily

FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug

Eli Lilly stock jumped Monday after FDA advisors said the benefits of Alzheimer's treatment donanemab outweigh the risks for most patients.

Investors Business Daily

Biogen Stock Continues Its 24% Sprint On A Twist In Alzheimer's Treatment

Biogen stock jumped Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.

Investors Business Daily

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Investors Business Daily

Highly Awaited Alzheimer's Drug Hit By Delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

International Business Times

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment

Biogen stock tumbled Thursday — pulling Prothena stock down — on mixed test results for an updated version of its Alzheimer's treatment.

The Independent UK

After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies

The Independent UK

Insurers won't cover new Alzheimer's treatment for some customers

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients

Investors Business Daily

Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates

Biogen stock dropped Tuesday after the biotechnology firm said it's eliminating 1,000 jobs as part of a strategy to cut operating expenses.

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Lilly applies for Alzheimer’s drug’s US approval after trial success

Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details of a final-stage trial at a conference in Amsterdam.

Tribune News Service

New Alzheimer’s drug is first to show it slows disease. But It’s facing a rocky rollout

Eisai Co.’s breakthrough Alzheimer’s drug — the first to show it slows the brain-destroying disease — is facing a rocky rollout as doctors grapple with logistical issues, insurance uncertainties and complicated safety testing requirements.

The Guardian - UK

New dementia drugs: patients to pay privately or face NHS postcode lottery

As advanced remedies emerge, the chief executive of Alzheimer’s Research UK warns sufferers could miss out as the health service struggles to cope

Daily Mirror

Miracle new Alzheimer's drug which slows cognitive decline of disease to be rolled out

The Food and Drug Administration (FDA) has approved the much awaited drug Leqembi which has been shown to slow the cognitive decline caused by Alzheimer’s, the most common type of dementia

Al Jazeera

US government approves Alzheimer’s drug to slow cognitive decline

Some insurances, including the government-run Medicare, refused to pay for the drug until it received full approval.

Tribune News Service

Eisai Alzheimer's drug gets full US approval, widening access to the therapy

Eisai Co.’s Alzheimer’s drug Leqembi gained full approval from U.S. regulators Thursday, a move expected to widen access to the first drug cleared based on its ability to slow progression of the mind-robbing disease.

Axios

FDA approves Leqembi, first drug to slow Alzheimer’s progression

Eisai and Biogen's Leqembi is the first drug to slow Alzheimer's progression to receive full FDA approval.

1 2 3 4

People

Chiquita BrooksLaSure

14 stories

Myles Minter

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

the Food and Drug Administration

166 stories

EMA

150 stories

Alzheimer Research UK

115 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.